AstraZeneca (AstraZeneca) Change In Payables And Accrued Expense : $0 Mil (TTM As of Mar. 2024)

View and export this data going back to 1993. Start your Free Trial

What is AstraZeneca Change In Payables And Accrued Expense?

AstraZeneca's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was $0 Mil. It means AstraZeneca's Accounts Payable & Accrued Expense stayed the same from Dec. 2023 to Mar. 2024 .

AstraZeneca's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $0 Mil. It means AstraZeneca's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Dec. 2023 .

AstraZeneca Change In Payables And Accrued Expense Historical Data

The historical data trend for AstraZeneca's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Change In Payables And Accrued Expense Chart

AstraZeneca Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

AstraZeneca Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

AstraZeneca Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

AstraZeneca Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

AstraZeneca (AstraZeneca) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (NAS:AZN) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

AZNCF:USA AZN:Sweden AZNN:Mexico AZNl:UK AZN:UK ZEGA:Germany ZEG:Germany ZEG:Germany ZEG:Germany ZEGA:Germany ZEG:Germany A1ZN34:Brazil

Address

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA

Website

https://www.astrazeneca.com

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.